TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7241441
Drug: Methohexitone administered
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone administered in increments based on body weight and time, with suxamethonium for relaxation.
Study: 7241441
Drug: Small aliquots
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small aliquots of lignocaine for reducing injection pain, given before or mixed with methohexitone.
Study: 31940502
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) + O2 for 24 hours
Study: 31017569
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B complex added to prime solution for CPB (25 mg vitamin B1, 2.734 mg vitamin B2, 5 mg vitamin B6, 15 mcg vitamin B12, 50 mg niacinamide, 17.2 mg D-panthenol)
Study: 24270456
Drug: Concurrent Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Strength and Endurance Training ratio 3:1 (CT3)
Study: 24270456
Drug: Concurrent Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Strength and Endurance Training ratio 1:1 (CT1)
Study: 19516185
Drug: Amlodipine-perindopril therapy
Normalized name: amlodipine / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine-perindopril therapy
Study: 19516185
Drug: Atenolol-thiazide therapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-thiazide therapy
Study: 15176293
Drug: Tuberculostatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculostatic drugs + vitamins C (1.0 g) and E (600 mg) after 1-month therapy
Study: 15176293
Drug: Tuberculostatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculostatic drugs
Study: 9724682
Drug: Urinary calcium
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary calcium excretion measurement
Study: 1785235
Drug: Unlimited access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Unlimited access to oral water until 2 hours before anaesthesia
Study: 7131548
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 mg) for high-nicotine-dependent smokers
Study: 7131548
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 mg) for low-nicotine-dependent smokers
Study: 22865999
Drug: Cognitive-motor exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-motor exercise program (twice weekly for 12 weeks) including strength and balance training and dance video gaming
Study: 17479539
Drug: New retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: New retard tablet formulation of verapamil (240 mg oral dose)
Study: 17479539
Drug: Standard retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard retard tablet formulation of verapamil (240 mg oral dose)
Study: 17479539
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) dose of verapamil (5 mg)
Study: 9113177
Drug: 0.125 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/kg morphine in 60 ml saline administered intravenously into the exsanguinated operative limb
Study: 9113177
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml saline administered intravenously into the operative leg and 0.125 mg/kg morphine intramuscularly into the opposite leg
Study: 2580181
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus a thiazide diuretic (37.5-75 mg/day)
Study: 2580181
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus a diuretic (60-120 mg/day)
Study: 2580181
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus a thiazide diuretic
Study: 2580181
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus a diuretic
Study: 26599222
Drug: Potassium supplementation
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplementation (2.8 g/day)
Study: 20410835
Drug: In-treatment EFS
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment EFS
Study: 20410835
Drug: In-treatment stress-corrected
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment stress-corrected EFS
Study: 20410835
Drug: In-treatment MWS
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment MWS
Study: 20410835
Drug: In-treatment stress-corrected
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment stress-corrected MWS
Study: 15943950
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment in a Primary Care Clinic (PCC) for 26 weeks
Study: 15943950
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment in an Opioid Treatment Program (OTP)
Study: 29685792
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 4000 IU daily for 12 months
Study: 29685792
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 2000 IU daily for 12 months
Study: 27737356
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures supported by two implants with bar‐clip system and a maxillary conventional denture (n = 25)
Study: 27737356
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures supported by two implants with bar‐clip system
Study: 15772563
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen 0.625 mg/d
Study: 8082084
Drug: Tumors weighing
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumors weighing less than 550 g
Study: 8082084
Drug: Tumors weighing
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumors weighing more than 550 g
Study: 12501880
Drug: Once-daily alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily alendronate 10 mg
Study: 7673615
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg/day for 8 weeks (GU) or 6 weeks (DU)
Study: 7673615
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy of lansoprazole 30 mg/day and amoxicillin (AMPC) 1 g/day or clarithromycin (CAM) 400 mg/day for 2 weeks
Study: 7673615
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of lansoprazole 30 mg/day, AMPC 1 g/day, or CAM 400 mg/day, and metronidazole 500 mg/day for 2 weeks
Study: 7032411
Drug: Metronidazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (single intravenous dose)
Study: 29898141
Drug: N‐acetylcysteine, vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐acetylcysteine, vitamin C and selenium (600 mg, 1500 mg, 0.5 mg respectively) administered orally twice a day from the day before to 2 days after surgery
Study: 29898141
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nothing administered)
Study: 27227933
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (9 mL/kg bicarbonate 154 mmol/L)
Study: 24703574
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² with vitamin B12 and folic acid q3w
Study: 24703574
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² with vitamin B12 and folic acid q3w + Erlotinib 150 mg daily
Study: 18235116
Drug: Imatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (100 to 800 mg daily)
Study: 15881476
Drug: clarithromycin ER
Normalized name: Clarithromycin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin ER 1000 mg once daily
Study: 12877665
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 30,000 IU subcutaneously once weekly (q.w.)
Study: 12877665
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 10,000 IU three-times weekly (t.i.w.)
Study: 7503620
Drug: verapamil 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 480 mg/day
Study: 7503620
Drug: metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 200 mg/day
Study: 1782922
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulphate 185.4 mg per day
Study: 6890407
Drug: Scopolamine delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine delivered by transdermal patch
Study: 30565793
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg/daily)
Study: 24608196
Drug: NEPA100 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA100 + PALO 0.50 mg
Study: 24608196
Drug: NEPA200 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA200 + PALO 0.50 mg
Study: 24608196
Drug: NEPA300 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA300 + PALO 0.50 mg
Study: 24608196
Drug: PALO 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALO 0.50 mg
Study: 24608196
Drug: APR +
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: APR + OND 32 mg
Study: 19605373
Drug: Supervised aquatic
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised aquatic training (3 weekly sessions of 60 min for 32 weeks)
Study: 15751168
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 IU, daily subcutaneous injections for 14 days)
Study: 11788639
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH (100 mcg/kg/day)
Study: 11788639
Drug: Post-GH treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-GH treatment
Study: 10517552
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (MOR) administration
Study: 10517552
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (MOR) administration
Study: 109598
Drug: Test regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test regimen of prednisone therapy (higher dosage, longer duration)
Study: 28673323
Drug: Bracelet- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bracelet- and self-directed observational therapy (BSDOT)
Study: 26519114
Drug: Aldosterone antagonist
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonist (spironolactone) in combination with RAAS blockers
Study: 26519114
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (RAAS blockers only)
Study: 21170603
Drug: Cr brewer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr brewer's yeast supplementation (500 μg Cr/person/day)
Study: 17200492
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day of zonisamide (ZNS)
Study: 17200492
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of zonisamide (ZNS)
Study: 17200492
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of zonisamide (ZNS)
Study: 2459557
Drug: Penticainide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penticainide (1.5 mg/kg)
Study: 2459557
Drug: Disopyramide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (1.5 mg/kg)
Study: 31830433
Drug: Knee brace
Normalized name: Knee Brace Large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee brace for 2 weeks during daily living, sports, or painful tasks
Study: 26368295
Drug: Methadone 10
Normalized name: normethadone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 10 mg (oral dose)
Study: 21292898
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine pyrimetamine (SP)
Study: 16856588
Drug: Only vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only vaginal misoprostol (400 microg 6 hourly up to 4 doses)
Study: 16856588
Drug: Oral plus
Normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral plus vaginal misoprostol (400 microg orally at 12 hour intervals for 2 doses, followed by 400 microg vaginally 6 hourly up to 4 doses)
Study: 14551000
Drug: Food and
Normalized name: ThickenUp Clear Instant Food and Beverage Thickener Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food and Drug Administration table with numbers
Study: 11018309
Drug: Lipo PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lipo PGE1 injection
Study: 11018309
Drug: Constant rate
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant rate infusion of PGE1 (10 ng kg(‐1) min(‐1))
Study: 11018309
Drug: Constant rate
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant rate infusion of PGE1 (50 ng kg(‐1) min(‐1))
Study: 9296473
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin dalteparin (Fragmin) for 3 months
Study: 9296473
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin dalteparin (Fragmin)
Study: 7690219
Drug: Propafenone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 600 mg/d (bid)
Study: 7690219
Drug: Propafenone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 600 mg/d (tid)
Study: 30057892
Drug: Rehabilitation programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation programme (exercise 1 h, twice weekly; education 1 h, once weekly)
Study: 11012557
Drug: Z13752A 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z13752A 200 mg
Study: 11012557
Drug: Z13752A 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z13752A 400 mg
Study: 11012557
Drug: Z13752A 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z13752A 600 mg
Study: 11012557
Drug: Z13752A 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z13752A 800 mg
Study: 11012557
Drug: Z13752A (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z13752A (all doses tested)
Study: 11012557
Drug: Z13752A (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z13752A (200-800 mg range)
Study: 8697547
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 micrograms.ml‐1 with bupivacaine 0.015% and epinephrine 2 micrograms.ml‐1
Study: 8697547
Drug: Sufentanil 1
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1 microgram.ml‐1 with bupivacaine 0.015% and epinephrine 2 micrograms.ml‐1
Study: 6435443
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (infused intravenously)
Study: 31645472
Drug: Phenylephrine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine administered intravenously to increase systolic blood pressure (SBP) up to 200 mm Hg
Study: 22395672
Drug: HAART and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART and chemotherapy (CXT) (Triomune plus bleomycin, doxorubicin, and vincristine every 3 weeks, or oral etoposide when not available)
Study: 19775480
Drug: Irinotecan-containing adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan-containing adjuvant chemotherapy
Study: 19775480
Drug: Adjuvant 5-FU-based
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant 5-FU-based chemotherapy (including irinotecan)
Study: 17213294
Drug: 2 item
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 item stage of change (SOC) questionnaire administered prior to ART and after 16 weeks of treatment
Study: 17044538
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) applied with Merocel soaked with 1.5 mL of MMC (0.4 mg/mL) for 5 minutes
Study: 17044538
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution applied as control
Study: 8678002
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus omeprazole (amoxicillin 500 mg p.o., t.i.d.; metronidazole 250 mg p.o., t.i.d.; bismuth subsalicylate 524 mg p.o., q.i.d.; omeprazole 20 mg p.o., q.d.)
Study: 8678002
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus omeprazole
Study: 1668656
Drug: sCT 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT 100 I.U. by nasal spray
Study: 1668656
Drug: sCT 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT 50 I.U. by intramuscular route
Study: 29879045
Drug: Qingfeijianpi decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingfeijianpi decoction (1 dose/day for 4 weeks)
Study: 29879045
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg once per day for 4 weeks)
Study: 27149266
Drug: DTPa and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa and OPV (co-administered with RIX4414)
Study: 27149266
Drug: OPV (co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPV (co-administered with RIX4414)
Study: 19815243
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg/d, n = 50)
Study: 19815243
Drug: Metformin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (maximum dose 2550 mg/d, n = 50)
Study: 16876479
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (G(1), N=6): 8 x 60% of T(max) at V.VO(2max), 1:1 work:recovery ratio
Study: 16876479
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (G(2), N=6): 12 x 30s at 130% V.VO(2max), 4.5 min recovery
Study: 16876479
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (G(CON), N=5): 60 min at 75% V.VO(2max)
Study: 12119808
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment technique (ART) using hand instruments
Study: 12119808
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment technique using rotary instruments
Study: 9917435
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine (DTaP + PRP-T)
Study: 9917435
Drug: Separate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate vaccines (DTaP and PRP-T)
Study: 7482998
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg weekly combined with proguanil 100 mg daily
Study: 7482998
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg weekly combined with proguanil 200 mg daily
Study: 7482998
Drug: Proguanil 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil 200 mg daily only
Study: 23423433
Drug: Killed Leishmania
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed Leishmania (Leishmania) amazonensis vaccine
Study: 11887037
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) therapy and Selenium (Se) supplementation
Study: 9170575
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg (125 mg x 2)
Study: 9170575
Drug: Flutamide 375
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 375 mg (125 mg x 3)
Study: 1751811
Drug: Rifaximin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (400 mg/8h)
Study: 6627697
Drug: Benserazide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benserazide (200 mg)
Study: 6627697
Drug: Metoclopramide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (1 mg)
Study: 31783823
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral esketamine as add-on to regular antidepressant medications for 6 weeks
Study: 31783823
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as add-on to regular antidepressant medications for 6 weeks
Study: 19290703
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) plus standard methadone treatment for 12 weeks
Study: 18416737
Drug: basiliximab, calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basiliximab, calcineurin inhibitor, sirolimus and steroids